Drug Overview
Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix. Launches throughout the EU and other countries have been staggered over 2014–16, while Trintellix remains in Phase III development in Japan. Trintellix was rebranded in the US in 2016 to distinguish itself from Brilinta (ticagrelor; AstraZeneca/The Medicines Company), after reports of medication confusion by healthcare professionals.
Trintellix was first discovered by Lundbeck and then co-developed with Takeda, which now markets the drug in the US. Trintellix is a multimodal serotonergic enhancer with activity at the serotonin receptors 5-HT3, 5-HT7, 5-HT1A, and 5-HT1B, and also at the serotonin transporter. This broad pharmacological profile results in an antidepressant activity and also the potential to improve cognitive performance among depressed patients.
Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix. Launches throughout the EU and other countries have been staggered over 2014–16, while Trintellix remains in Phase III development in Japan. Trintellix was rebranded in the US in 2016 to distinguish itself from Brilinta (ticagrelor; AstraZeneca/The Medicines Company), after reports of medication confusion by healthcare professionals.
Trintellix was first discovered by Lundbeck and then co-developed with Takeda, which now markets the drug in the US. Trintellix is a multimodal serotonergic enhancer with activity at the serotonin receptors 5-HT3, 5-HT7, 5-HT1A, and 5-HT1B, and also at the serotonin transporter. This broad pharmacological profile results in an antidepressant activity and also the potential to improve cognitive performance among depressed patients.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
